Skip to main content
Fig. 2 | Clinical Epigenetics

Fig. 2

From: Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients

Fig. 2

MSP and dp_qMSP examples in the analyzed tumor samples for patients 98 and 99. a Example of MGMT promoter methylation in acrylamide gel. The MSP products were loaded and electrophoresed as follows: sample number 98 (lanes 1–4 unmethylated and methylated reactions performed by duplicated), sample number 99 (lanes 5–8, unmethylated and methylated reactions performed by duplicated), lanes 9–10 correspond to unmethylated and methylated reactions using a FFPE negative control sample. Lanes 11 and 12 correspond to unmethylated and methylated reactions using a PBMC control sample. Lane 13 corresponds to PBMC methylated in vitro (IVD) as a positive control, and last line is the water methylation reaction used to discard contamination. b, c. Example of methylated and unmethylated amplification by qMSP. B. Patient number 98, FAM (M) and VIC (U) probes amplified (47.9% methylation). c Patient number 99, only VIC probe amplified (0% methylation). U: Unmethylated. M: methylated. FFPE: Formalin fixed paraffin embedded. PBMCs: Peripheral blood mononuclear cells. NC: negative control. IVD: In vitro Methylated DNA (positive control). NTC (No Template Control)

Back to article page